Ep. 167 - The IRA, T Cell Therapies & The Distillery
BioCentury This Week
English - March 21, 2023 00:00 - 22 minutes - 15.4 MB - ★★★★★ - 11 ratingsScience biotech biopharma pharmaceutical research investment dealmaking Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 166 - SVB Shakeout: Next Steps for Biotech
Next Episode: Ep. 168. - VCs' Take on SVB & New ALS Endpoint
On the latest BioCentury This Week podcast, BioCentury’s editors assess how companies are upending pipeline and business strategies due to the Inflation Reduction Act, along with other takeaways from a survey on the IRA’s implications, conducted by BioCentury with the support of BIO. They also discuss CMS’s memo outlining how it intends to implement the IRA’s price-setting provisions, the T cell therapy landscape and insights from BioCentury’s Distillery. This week’s podcast is sponsored by Jeito Capital.